Regulatory Information
MEDOCHEMIE SINGAPORE PTE. LTD.
MEDOCHEMIE SINGAPORE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
TABLET
**4.2. Posology and method of administration** SELEGOS 10mg (2 tablets) daily either alone or as an adjunct to levodopa or levodopa/peripheral decarboxylase inhibitor. SELEGOS may be administered either as a single dose in the morning or in two divided doses of 5mg taken at breakfast and lunch. When SELEGOS is added to a levodopa regimen it is possible to reduce the levodopa dosage by an average of 30 percent.
ORAL
Medical Information
**4.1. Therapeutic indications** SELEGOS is indicated for the treatment of Parkinson’s disease or symptomatic parkinsonism. SELEGOS may be used alone in early Parkinson’s disease to delay the need for levodopa (with or without decarboxylase inhibitor). SELEGOS may also be used as an adjunct to levodopa (with or without decarboxylase inhibitor).
**4.3. Contraindications** None.
N04BD01
selegiline
Manufacturer Information
MEDOCHEMIE SINGAPORE PTE. LTD.
MEDOCHEMIE LTD
Active Ingredients
Documents
Package Inserts
Selegos Tablet PI.pdf
Approved: August 26, 2021